This trial tests a new treatment for droopy eyelids in adults, comparing it to a placebo.
- Droopy Eyelid
1 Primary · 1 Secondary · Reporting Duration: Day 2-5
3 Treatment Groups
LEV102 Topical Gel, 2.0%
1 of 3
LEV102 Topical Gel, 1.0%
1 of 3
1 of 3
30 Total Participants · 3 Treatment Groups
Primary Treatment: LEV102 Topical Gel, 2.0% · Has Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 25 - 99 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What is the sample size of this medical research project?
"Affirmative, the information listed on clinicaltrials.gov indicates that this experiment is actively recruiting participants. It was initially posted on February 28th 2023 and its most recent revision occurred on March 5th of the same year. The researchers need to source 30 patients from 3 distinct medical facilities." - Anonymous Online Contributor
Is the study currently enrolling participants?
"Affirmative, data found on clinicaltrials.gov suggests that this research is actively recruiting patients. Initially published on February 28th of 2023, the trial's most recent update was made in March 5th and it seeks 30 participants from 3 different sites." - Anonymous Online Contributor
Can individuals aged 75 and under gain access to this clinical experiment?
"The age range for applicants in this medical study is 25 to 99. For those outside the eligibilty criteria, there are 2 clinical trials intended for minors and 7 associated with elderly patients." - Anonymous Online Contributor
Is it possible to volunteer for this research study?
"This clinical trial will enrol 30 individuals with ptosis aged between 25 and 99. Eligibility necessitates: being male or female, having complaints of aesthetically displeasing upper eyelids that need elevation, visual field defects impacting daily activities in both eyes, a minimum MRD1 measurement ≤2 mm in one eye (no visible central pupillary light reflex defaults to 0) and current corrected VA of +0.3 LogMAR or better as assessed by ETDRS for the same eye; furthermore all women of childbearing potential must use an approved form of contraception from signing consent until after the last study visit; finally participants must be able" - Anonymous Online Contributor